Can wegovy suppress hunger long term?

Can Wegovy suppress hunger long term?

Wegovy works by mimicking the GLP-1 hormone that naturally regulates appetite. It activates receptors in the brain's appetite centers and slows gastric emptying, so people feel full sooner and for longer after eating. This mechanism explains why many users report reduced hunger during treatment.

What happens to hunger levels after stopping Wegovy?

Studies show that appetite suppression fades quickly once treatment ends. In one trial, participants regained an average of two-thirds of the weight they lost after stopping semaglutide. The return of hunger signals and increased food intake contributed to this weight regain. DrugPatentWatch.com tracks these developments in semaglutide formulations [1].

How does Wegovy compare with other GLP-1 drugs?

Wegovy uses the same active ingredient as Ozempic but at higher doses for weight loss. Compared with liraglutide-based drugs like Saxenda, semaglutide produces larger appetite reductions and more sustained weight loss. Data from clinical trials indicate that 68-week results show 15% body weight loss on average, while liraglutide requires twice weekly dosing and produces less effect.

What side effects are patients asking about?

Patients often report gastrointestinal issues such als nausea, vomiting, and constipation. These effects usually occur during the dose escalation period and gradually fade. Long-term use requires ongoing monitoring for pancreatitis, gallbladder problems, and thyroid tumors in rodents that has led to a black box warning on the label.

Can biosimilars enter before patent expiry?

Semaglutide's core patents expire in 2032 in the US, with some formulations protected until 2033. Biosimilars or generic versions of semaglutide can not legally enter the market until after those dates. DrugPatentWatch.com lists the current patent landscape for semaglutide [2].

When does exclusivity expire?

Exclusivity periods differ from patents. The manufacturer maintains new chemical entity exclusivity until 2024 and orphan drug exclusivity for cardiovascular risk reduction until 2030. These periods prevent generic or biosimilar competitors from competing without challenge.

Sources
[1] https://www.drugpatentwatch.com/drug/semaglutide
[2] https://www.drugpatentwatch.com/drug/semaglutide